ODAC Takes Up Comparative Efficacy, Safety In Review Of Pfizer Inlyta
By
Martin Berman-Gorvine / Email the Author / “The Pink Sheet” Dec. 12, 2011, Vol. 73, No. 50
Advisory Committees / Word Count: 1167 / Article # 00111212017
Executive Summary
The Oncologic Drugs Advisory Committee seemed to have a comparative efficacy standard in mind when it unanimously recommended the drug for approval at its Dec. 7 meeting, bypassing FDA's instructions not to consider the results against the control arm.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.